Ruxolitinib (Jakavi®) for Polycythaemia Vera. HTA ID: 20008
Ruxolitinib (Jakavi®) is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
Rapid Review
| Commenced | Completed | Outcome |
| 15/04/2015 | 28/05/2015 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 13/04/2016 | 16/08/2016 | Reimbursement Not Recommended |
Resubmission of HTA
| NCPE Assessment Process | Complete |
| Resubmission of HTA commissioned by HSE/ | 04/03/2020 |
| Pre-submission consultation with Applicant | 09/03/2020 |
| Full HTA submission received from applicant | 16/09/2020 |
| Preliminary review sent to applicant | 01/04/2021 |
| NCPE assessment re-commenced | 04/05/2021 |
| Follow-up preliminary review sent to Applicant | 19/05/2021 |
| NCPE assessment re-commenced | 26/05/2021 |
| Factual accuracy sent to Applicant | 28/06/2021 |
| NCPE assessment re-commenced | 09/07/2021 |
| NCPE assessment completed | 21/07/2021 |
| NCPE assessment outcome |
The NCPE recommends that ruxolitinib (Jakavi®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.